These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43 related articles for article (PubMed ID: 10813041)
21. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058 [TBL] [Abstract][Full Text] [Related]
22. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. Borman AM; Paulous S; Clavel F J Gen Virol; 1996 Mar; 77 ( Pt 3)():419-26. PubMed ID: 8601776 [TBL] [Abstract][Full Text] [Related]
23. Invirase resistance/cross-resistance data released. AIDS Patient Care STDS; 1996 Jun; 10(3):185. PubMed ID: 11361626 [No Abstract] [Full Text] [Related]
28. Highlights of the Fourth International Workshop on HIV Drug Resistance. Lange JM; deJong MD J Int Assoc Physicians AIDS Care; 1995 Aug; 1(7):25-7. PubMed ID: 11362748 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and HIV protease inhibitory activity of new 4-hydroxy-2-pyrone derivatives. Lee YS; Kim SN; Lee YS; Lee JY; Lee CK; Kim HS; Park H Arch Pharm (Weinheim); 2000 Oct; 333(10):319-22. PubMed ID: 11092133 [No Abstract] [Full Text] [Related]
31. New resistance score for tipranavir. Poveda E AIDS Rev; 2008; 10(2):127. PubMed ID: 18615125 [No Abstract] [Full Text] [Related]
32. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. Back NK; van Wijk A; Remmerswaal D; van Monfort M; Nijhuis M; Schuurman R; Boucher CA AIDS; 2000 Jan; 14(1):101-2. PubMed ID: 10714580 [No Abstract] [Full Text] [Related]
33. The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line. Mazza F; Tronconi E; Valerio A; Groettrup M; Kremer M; Tossi A; Benedetti F; Cargnel A; Atzori C J Eukaryot Microbiol; 2006; 53 Suppl 1():S144-6. PubMed ID: 17169036 [No Abstract] [Full Text] [Related]